View Older Stories View More Recent Stories

May 5, 2020 06:45AM Merck Commits Additional $10 Million to COVID-19 Relief Efforts to Help Disparately Impacted Patients and Communities
Apr 28, 2020 05:08PM Merck (MRK) Announces FDA Approves KEYTRUDA for Use at Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications
Apr 28, 2020 04:35PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications
Apr 28, 2020 06:45AM Merck Announces First-Quarter 2020 Financial Results
Apr 27, 2020 06:57AM Merck (MRK) Announces First Clinical Outcomes Evaluating Six-Week Dosing Schedule for KEYTRUDA Presented at AACR
Apr 27, 2020 06:55AM First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I
Apr 27, 2020 06:46AM Merck (MRK), Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers
Apr 27, 2020 06:45AM Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers
Apr 24, 2020 06:56AM Merck (MRK) Announces LYNPARZA Demonstrated OS Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Apr 24, 2020 06:55AM LYNPARZA® (Olaparib) Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Apr 24, 2020 06:55AM LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Apr 23, 2020 06:49AM Merck (MRK) Resubmits sBLAs for KEYTRUDA Six-Week Dosing Schedule
Apr 23, 2020 06:45AM Merck Resubmits Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule
Apr 21, 2020 06:45AM Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts
Apr 15, 2020 06:50AM Merck (MRK) Reports US Launch of ONTRUZANT (trastuzumab-dttb), a Biosimilar of Herceptin® (trastuzumab)
Apr 15, 2020 06:45AM Merck Announces US Launch of ONTRUZANT® (trastuzumab-dttb), a Biosimilar of Herceptin® (trastuzumab)
Apr 13, 2020 06:57AM AstraZeneca (AZN), Merck (MRK) Announce KOSELUGO Approved by FDA for Pediatric Patients Two Years and Older With NF1 and Symptomatic, Inoperable PN
Apr 13, 2020 06:55AM KOSELUGO® (selumetinib) Approved by FDA for Pediatric Patients Two Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas
Apr 9, 2020 08:00AM Merck Announces $3M Commitment to Address Critical Maternal Health Needs During COVID-19 Pandemic
Apr 9, 2020 06:13AM Pfizer (PFE), EMD Serono Granted FDA Breakthrough Therapy Designation & Submit Application for BAVENCIO
Apr 9, 2020 06:00AM EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Apr 7, 2020 08:00AM MilliporeSigma Awarded Second U.S. Patent for CRISPR Gene-Editing Technology
Apr 7, 2020 06:45AM Merck (MRK) Receives Priority Review from FDA for Second Application for KEYTRUDA Based on Biomarker
Apr 7, 2020 06:45AM Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type
Apr 2, 2020 06:46AM Merck (MRK) Announces KEYTRUDA Significantly Improved PFS as First-Line Treatment for MSI-H or dMMR Colorectal Cancer
Apr 2, 2020 06:45AM Merck Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (d
Apr 2, 2020 06:30AM Merck to Hold First-Quarter 2020 Sales and Earnings Conference Call on April 28
Apr 1, 2020 04:00PM Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Apr 1, 2020 04:00PM Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Mar 30, 2020 06:11AM Merck (MRK) Reports Investigational Drug Vericiguat Significantly Reduced the Risk of Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death
Mar 28, 2020 10:00AM Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with A
Mar 25, 2020 05:00PM Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response
Mar 22, 2020 11:52AM Merck Donates a Half a Million Masks to Support COVID-19 Emergency Response in New York City
Mar 20, 2020 05:01PM Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
Mar 17, 2020 06:46AM Merck (MRK) Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant
Mar 17, 2020 06:45AM Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough
Mar 13, 2020 08:00AM EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Mar 12, 2020 05:59AM Merck (MRK), AstraZeneca (AZN) Report Update on Phase 3 GY004 for Cediranib & LYNPARZA (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
Mar 12, 2020 03:00AM Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
Mar 4, 2020 06:45AM Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents that Block Multiple Stages of the Lifecycle of the Parasite
Mar 3, 2020 02:00PM MilliporeSigma's New LANEXO™ System to Improve Scientists' Productivity in the Lab
Mar 2, 2020 06:45AM Merck Announces New Data from Broad HIV Program at CROI 2020
Mar 2, 2020 06:31AM Merck's (MRK) KEYTRUDA Significantly Improved PSF Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory cHL
Mar 2, 2020 06:30AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
Feb 27, 2020 06:45AM Merck to Present at the Cowen Health Care Conference
Feb 18, 2020 07:17PM Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule
Feb 14, 2020 11:20AM ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification
Feb 12, 2020 06:52AM Merck's (MRK) KEYTRUDA in Combination with Chemotherapy Met Primary Endpoint of PFS as First-Line Treatment for mTNBC
Feb 12, 2020 06:45AM Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNB
Feb 5, 2020 06:47AM Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results
View More Recent Stories View Older Stories